Sign In
Buy ABBV
$250.88
-6.74 (-2.61%)
At Close: Jul 31, 2026
Why AbbVie Stock Slumped Today
07:41pm, Friday, 31'st Jul 2026
It posted a second-quarter earnings report that raised some concerns. One was a miss on the consensus bottom-line estimate.
AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript
04:23pm, Friday, 31'st Jul 2026
AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript
AbbVie Inc (ABBV) (Q2 2026) Earnings Call Highlights: Robust Growth Driven by Skyrizi and Rinvoq, Pipeline Advances
04:01pm, Friday, 31'st Jul 2026
Release Date: July 31, 2026For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbbVie Inc (ABBV
ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down
02:16pm, Friday, 31'st Jul 2026
AbbVie tops Q2 earnings and revenue estimates on strong immunology drug sales, but a lower 2026 EPS outlook tied to the Apogee deal weighs on shares.
Pre-Market Trading Up in Final Session of the Week
11:36am, Friday, 31'st Jul 2026
Despite some mid-week turbulence, we're trading fairly even with where we were as of mid-day Monday.
AbbVie Q2 Earnings Call Highlights
11:05am, Friday, 31'st Jul 2026
AbbVie NYSE: ABBV reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
11:01am, Friday, 31'st Jul 2026
The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH?
10:55am, Friday, 31'st Jul 2026
FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.
AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat
10:16am, Friday, 31'st Jul 2026
AbbVie Inc. (NYSE:ABBV) shares are retreating Friday as a modest reduction to full-year adjusted EPS guidance that pushed the midpoint beneath the analyst target proved enough to sour the market's moo
AbbVie Beats but Cuts Guidance on $10.9 Billion Acquisition
10:03am, Friday, 31'st Jul 2026
AbbVie (ABBV) fell 3.46% premarket after trimming full-year guidance alongside second-quarter results that beat on both lines. Net revenues rose 10.2% to $16.99
AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates
09:55am, Friday, 31'st Jul 2026
AbbVie (ABBV) came out with quarterly earnings of $3.65 per share, beating the Zacks Consensus Estimate of $3.64 per share. This compares to earnings of $2.97 per share a year ago.
AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps
08:36am, Friday, 31'st Jul 2026
AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.
AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.
08:31am, Friday, 31'st Jul 2026
AbbVie cuts its full-year guidance to account for its pending acquisition of Apogee Therapeutics.
AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates
07:50am, Friday, 31'st Jul 2026
AbbVie trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics acquisition, while topping second-quarter estimates on strong immunology drug sales.
AbbVie Reports Second-Quarter 2026 Financial Results
07:47am, Friday, 31'st Jul 2026
Reports Second-Quarter Diluted EPS of $2.03 on a GAAP Basis, an Increase of 290.4 Percent; Adjusted Diluted EPS of $3.65, an Increase of 22.9 Percent; These Results Include an Unfavorable Impact of $0
